Partial-onset Seizures
📧 Sign up to get email alerts when something new happens for Partial-onset Seizures.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2015-12-04FDA Approved: OXTELLAR XR — Supplemental Application (Supernus Pharmaceuticals, Inc.)
FDA approved a supplemental application for OXTELLAR XR (oxcarbazepine) submitted by Supernus Pharmaceuticals, indicating an approved update…
-
FDA approval · 2015-10-02FDA Approved: LEVETIRACETAM — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal Pharmaceuticals LLC's supplemental application for levetiracetam, a generic form of the antiepileptic drug, under up…
-
FDA approval · 2015-09-10FDA Approved: APTIOM — Supplemental Application (Sumitomo Pharma America, Inc.)
FDA approved a supplemental application for APTIOM (eslicarbazepine acetate) from Sumitomo Pharma America, Inc., signaling an update to the …
-
FDA approval · 2015-08-13FDA Approved: LEVETIRACETAM — Original Application (Fresenius Kabi USA, LLC)
The FDA approved Fresenius Kabi USA, LLC's generic levetiracetam, expanding access to an anticonvulsant used to treat various seizure disord…
-
FDA approval · 2015-07-09FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a Supplemental Application for VIMPAT (lacosamide) filed by UCB, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-07-09FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) filed by UCB, Inc.
-
FDA approval · 2015-06-19FDA Approved: FYCOMPA — Supplemental Application (Eisai Inc.)
The FDA approved a supplemental application for FYCOMPA (perampanel) from Eisai Inc., resulting in an updated labeling for the drug.
-
FDA approval · 2015-06-19FDA Approved: ZONEGRAN — Supplemental Application (Advanz Pharma (US) Corp.)
FDA approved a supplemental application for Zonegran (zonisamide) from Advanz Pharma (US) Corp.
-
FDA approval · 2015-06-13FDA Approved: ZONISAMIDE — Supplemental Application (Exelan Pharmaceuticals, Inc.)
FDA approved a supplemental application for Zonisamide submitted by Exelan Pharmaceuticals, Inc. under ANDA 077869.
-
FDA approval · 2015-06-11FDA Approved: APTIOM — Supplemental Application (Sumitomo Pharma America, Inc.)
FDA has approved a Supplemental Application for APTIOM (eslicarbazepine acetate) from Sumitomo Pharma America, expanding labeling/indication…
-
FDA approval · 2015-06-04FDA Approved: LEVETIRACETAM — Original Application (Major Pharmaceuticals)
FDA approved the Original Application for levetiracetam from Major Pharmaceuticals, making a generic version of the anticonvulsant available…
-
FDA approval · 2015-04-15FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc.
-
FDA approval · 2015-04-14FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) filed by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2015-03-10FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA XR (levetiracetam) from UCB, authorizing an extended-release formulation for use in epile…
-
FDA approval · 2015-02-04FDA Approved: OXCARBAZEPINE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for oxcarbazepine submitted by Amneal Pharmaceuticals LLC, expanding the regulatory authorizatio…
-
FDA approval · 2015-01-20FDA Approved: OXCARBAZEPINE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved a supplemental application for oxcarbazepine from Glenmark Pharmaceuticals Inc., USA (ANDA 077802).
-
FDA approval · 2014-09-25FDA Approved: LEVETIRACETAM — Supplemental Application (Civica, Inc.)
FDA approved a Civica, Inc. supplemental application for Levetiracetam, approving changes to the generic product. The product is indicated f…
-
FDA approval · 2014-08-29FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc., indicating an approval of a supplement to the drug’s…
-
FDA approval · 2014-08-12FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) by UCB, Inc., authorizing changes to the labeling and/or addition of indicat…
-
FDA approval · 2014-08-12FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc. The action updates the product labeling with the new …
-
FDA approval · 2014-08-07FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for KEPPRA (levetiracetam) from UCB, Inc., potentially expanding labeling or indications.
-
FDA approval · 2014-06-04FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA Supplemental Application approval for VIMPAT (lacosamide) by UCB, Inc.
-
FDA approval · 2014-05-08FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Trileptal (oxcarbazepine) submitted by Novartis Pharmaceuticals Corporation, resulting in ch…
-
FDA approval · 2014-01-16FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc.
-
FDA approval · 2013-11-08FDA Approved: APTIOM — Original Application (Sumitomo Pharma America, Inc.)
FDA approved APTIOM (eslicarbazepine acetate) from Sumitomo Pharma America as an original NDA for use in adults with partial-onset seizures …